Octave® Receives $10 Million Grant from The Michael J. Fox Foundation to Develop and Validate  Biomarker Test for Parkinson’s Disease. Learn More

Apr 02nd, 2022

Optimal management of MS is lacking. Octave’s first-in-class, fully integrated comprehensive Precision Care Solution for the personalized treatment of multiple sclerosis is designed to address the MS ecosystem, providing physicians, patients, insurers and pharmaceutical companies with objective metrics for improved management decisions. Learn more about our comprehensive solution from Nature: https://go.nature.com/350VE6N

Get in Touch

Please reach out and we’ll be in touch soon.